Pro-life advocates are set to gather with White House officials on Friday amid mounting concerns that President Trump hasn’t pursued their agenda with sufficient intensity, particularly regarding enhanced abortion restrictions and stronger enforcement of current regulations.
The scheduled discussion follows recent criticism from Marjorie Dannenfelser, who leads Susan B. Anthony Pro-Life America, a prominent advocacy organization. Speaking to the Wall Street Journal, Dannenfelser pointed out that abortion numbers have increased nationwide following the Supreme Court’s 2022 decision to overturn Roe v. Wade, stating bluntly that “Trump is the problem.”
These developments highlight rising friction between Trump and segments of the anti-abortion community that previously served as crucial political supporters during his initial White House bid.
Though activists acknowledge Trump’s role in facilitating Roe’s reversal through his Supreme Court nominees, several organizations argue his administration hasn’t delivered on promised federal measures to limit abortion availability, particularly regarding stricter controls on the abortion medication mifepristone and crackdowns on internet-based pill distribution.
White House representative Allison Schuster pushed back against these criticisms, defending the administration’s accomplishments.
“President Trump is the most pro-life and pro-family president in American history, and his Administration has announced a series of bold actions to safeguard life and uphold Americans’ fundamental freedoms, including ending federal funding of abortion abroad,” Schuster stated.
Susan B. Anthony Pro-Life America declined to provide additional comments when contacted.
Research from the Guttmacher Institute indicates abortion procedures have actually increased since the high court’s 2022 decision that eliminated nationwide abortion protections. The organization estimates approximately 1,126,000 abortions were performed by medical providers in 2025, marking the highest total since 2009. This surge stems primarily from greater reliance on abortion medications, which now represent 65% of all procedures in states where abortion remains legal.
Political pressure has intensified recently as Republican legislators and anti-abortion organizations urge the Food and Drug Administration to reconsider safety protocols for mifepristone, the drug involved in more than half of American abortions. Senate Republicans initiated an investigation into abortion pill manufacturers in March while calling on the FDA to restrict online medication sales.
The mifepristone controversy has grown following multiple court decisions regarding mail-order availability of the medication.
Earlier this week, the U.S. Supreme Court issued a temporary order maintaining access to the drug via telemedicine and postal delivery while legal challenges proceed.
